Hospital mortality and resource use in subgroups of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial.

@article{Laterre2004HospitalMA,
  title={Hospital mortality and resource use in subgroups of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial.},
  author={P. F. Laterre and Howard I Levy and Gilles Clermont and Daniel E. Ball and Rekha Garg and David R. Nelson and Jean-François Dhainaut and Derek C. Angus},
  journal={Critical care medicine},
  year={2004},
  volume={32 11},
  pages={2207-18}
}
OBJECTIVE To compare differences in hospital mortality and resource use in adult severe sepsis subjects randomized to receive drotrecogin alfa (activated) (DrotAA) or placebo in the PROWESS trial. DESIGN Retrospective, cross-sectional, blinded follow-up of subjects enrolled in a previous randomized, controlled trial. SETTING One hundred sixty-four tertiary care institutions in 11 countries. PARTICIPANTS The 1,690 subjects with severe sepsis enrolled and treated with study drug in PROWESS… CONTINUE READING

From This Paper

Topics from this paper.
30 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 30 extracted citations

Similar Papers

Loading similar papers…